Andrew King promoted to President, R&D at Jade Biosciences

Jade Biosciences, Inc.

Andrew King previously CSO and Head of R&D appointed President Research & Development effective April 18 2026
No changes to Dr Kings compensation were made in connection with the appointment
King holds BVMS and Ph.D degrees and continues to lead R&D with expanded title

item 5.02

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-168351

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.